|
1. Gerovital-H3,
its regenerative effects
2. Gerovital-H3, anti-depressant effects
3. Gerovital-H3,
creator Ana Aslan's life
4. Gerovital-H3, treatment in osteoarthritis
5. Old
age humoral dismetabolism (GH-3)
6. Gerovital-H3
treatment in rheumatology
7. Gerovital-H3
- classic antiaging medicine
Gerovital - H3 treatment in Osteoarthritis
by Mircea Dumitru M.D., PhD.
to order
In 1946, Aslan published her first research on
Novocaine (1). In 1951, she studied the effect of procaine on experimental arthritis (2).
"After the first results with Novocaine
injections, I tried this treatment on patients with arthritis and those with a tendency to
ankylosis. Because these diseases are chronic, I administered novocaine for each patient
with more injections. With great joy, I noticed an improvement in the local symptoms, and
even more importantly a great improvement in their overall general condition. Before the
treatment, the patients avoided any movement due to pain and now they were willing and
wanting to walk, sitting up to read and talking. The biggest reward was noticing an
increase in their interest in life and for their family".
Aslan remembered, too: "On April 15, 1949- an
American GI, with arthritis arrived in my clinic. He had terrible pains and his
articulations were blocked. I explained to him my ideas about novocaine and after
receiving his permission, I gave him an intra-arterial injection with 1-% novocaine. After
10 to 15 minutes, his knee was mobile and he could flex his leg outright. What happiness!
I administered his treatment for a further two weeks and he was completely recovered"
(3).
Clinical (5,6,7,8,9) and experimental studies (2,10)
previously conducted by Aslan et al. have pointed out the effects of Gerovital-H3 therapy
in arthritis. Concerning the chronic degenerating disease under the effect of the
eutrophic Gerovital-H3 treatment, an obvious amelioration of the clinical signs was
particularly noticed in osteoarticulary diseases (11,12,13). In a study performed in 1982
(4) on 2643 patients, Aslan noticed that it became evident that pains ceased in 62.2% of
the patients, and articulary mobility and periarticulary muscular tonus were ameliorated
in 51.8% of the cases. Repeated radiological examinations indicated a gradual amelioration
of osteoporosis and other dystrophic osteoarticulary modifications.
I conducted a study on 100 elderly patients admitted
to the National Institute of Gerontology and Geriatrics (NIGG) in Bucharest. They were
aged 60 to 89 and suffering from moderate to severe arthritis involving one or more
joints. Two groups of 50 patients were made up being very similar in age, sex and
rheumatic diseases.
In both groups, arthritis involved more often the
spine than the peripheral joints, in which hip-arthritis was slightly less prevalent than
knee-arthritis, the latter being more frequent in women than men did. Patients with severe
organ or system pathology were not included. No patient with abarticular rheumatism was
included in the groups under study, nor patients with clinical, paraclinical or
radiological signs suggesting another type of rheumatism, nor those having a positive test
for the rheumatoid arthritis. I noted a significant number of patients suffered from
Heberdenosis, which was much more frequent in women than in men.
Two reasons for admission of the patients included
pains in the affected joints, limitation of movements, myalgia, joint swelling and
declining muscular strength. The patients under study were divided into the following
clinical forms who display joint pains persisting at rest; moderate limitation of
movements (with 10% to 30% of the normal joint movement capacity; accompanying phenomena
which point to ‘warm up’ arthritis processes-rubor, swelling, heat; reduction of
joint space and the presence of osteophytes (diagnosed radiologically). Severe forms with
marked pains; who display over 30% deficits of joint function; marked joint swelling; a
certain degree of invalidity that forced the patient to use an aid such as a stick or
frame- for walking.
Radiologically, the patients displayed reduction of
joint space and osteophytosis.
The distribution of these two clinical forms was
sensibly equal.
As far as associated morbidity of the patients is
concerned, the obvious prevalence of cardio-vascular diseases was first followed in order
by neuro-psychiatric, respiratory and digestive complaints.
Gerovital-H3 treatment was administered to the
patients in the first group as follows: one i. m. injection daily in the morning for 18
days, followed by 12 days of Gerovital-H3 pills, twice daily: 9:00 A.M. and 4:00 P.M.
Similarly, the patients in the second group received Placebo injections and pills. No
other drug was given, nor any local therapy applied.
Treatment efficacy was assessed by comparing prior
and post-treatment values of the following parameters recorded in all patients of the two
groups:
•pain as a subjective parameter and its
characteristics;
•joint mobility assessed by goniometry and
movements based on tests specific to each joint;
•muscular tone by muscular check-up;
•accompanying phenomena: joint swelling,
instability, crepitations;
•overall functional capacity of joints affected
by arthritis.
Some parameters reflecting the patients’
general condition such as arterial blood pressure, cyrcadian rhythms and psychic state
were also checked in parallel. In the two groups (Gerovital-H3 and Placebo) the clinical
signs of progress was recorded as the following:
In the Gerovital-H3 group the following was
recorded:
(1). Pain: A remarkable alleviation in 34% of cases,
satisfactory alleviation in 54% of cases and no effect in just 12% of the cases;
(2). Joint Mobility: Improved in 56% of cases and
remaining unchanged in the rest;
(3). Muscular Tone: Improved in 41% of cases and no
change in the rest.
I didn’t notice any side effects during the
treatment with Gerovital-H3.
For the Placebo group:
(1). Pain: A satisfactory alleviation in only 11% of
cases and no influence upon the remaining ones;
(2). Joint Mobility: Improved in only 4% of cases
and there was no change for the rest;
(3). Muscular Tone: Unchanged in 100% of the
patients.
Conclusions
Clinical symptoms dominated by pain and limitation
of movements was positively influenced in the case of the first group of patients, (i.e.
those under Gerovital-H3 treatment). Their psychic condition was obviously improved. The
small amount of positive outcomes recorded in the patients from the second group, (i.e.
the Placebo group) by the slight alleviation of joint pains can be explained in terms of
the patients resting while hospitalized, which is likely to have diminished the degree of
pain felt.
Previous studies carried out at the National
Institute of Gerontology and Geriatrics in Bucharest have proved that Gerovital-H3 exerts
a beneficial effect on the vascular, nervous and metabolic components involved in the
genesis of degenerative rheumatism (4,6,7,8,10,11,12). The positive properties of
Gerovital-H3 treatment can be explained as:
(A). The antalgo action either controlling or
reducing the pain caused by irritation of the nervous network from the spongious or by
osteophitic presence;
(B). The anti-inflammatory effect exerted through
the AMPc, stimulated by the moderate rise in circulating catecholamine levels;
(C). Improvement of capillary permeability and the
favourable intervention in the bioenzymatic disorders at the level of the joint cartilage
considered primum movens in the process of joint degeneration.
Gerovital-H3 can be the drug of choice in the
management of arthritis in Geriatrics, because of its beneficial effects on the
distressing, sometimes invalidating clinical phenomena and because of its paucity of side
effects.
REFERENCES
1. Aslan A., Rosenzweig S.: L’action de la
novocaine injectee hans la veine chez l’homme. Bull. Acad. Med. Roumaine, 1946, 7, p.
891-900.
2. Aslan A. et al.: The effects of procaine on
experimental arthritis induced in albino rats. Com. Acad. Romainia, 1950. 1, 11-12, p.
1110-1116.
3. Aslan A. et al.: Intra-atrerial treatment with
procaine in arthritis. Bull. St. Acad. Bucharest, 1950, II, 7, p. 891.
4. Aslan A. et al.: Peculiarities of chronic
degenerative rheumatism in the aged and the efficiency of Gerovital-H3 therapy. Romanian
J. Geront. & Geriatrics, 1982, 3, 1, 3-13.
5. Aslan A., David C.: Ergebnisse der
Novocainbehandlung-Stoff H3- bei dysmetabolischen Arthropathien. Therapie Woche-Karlsruhe,
1957, 8, 19-23.
6. Aslan A.: Longitudinal Study in the National
Institute of Gerontology & Geriatrics of Romania. J. Geront. & Geriatrics. 1980,
1, 2, 179-187.
7. Aslan A. et al.: The Parenteral Therapy with
Gerovital-H3 in the Aged with Degenerative Rheumatism. Romanian J. Geront. &
Geriatrics. 1983, 4, 3, 151-158.
8. Barsan M., Rodica P.: Cervical
Spondylodiskarthrosis in the Elderly and Gerovital-H3 Treatment. Romanian J. Geront. &
Geriatrics. 1985, 6, 1, 35-42.
9. Aslan A.: The Therapeutics of Old Age. The Action
of Procaine. Congr. of the Intern. Assoc. of Geront., 1960, San Francisco. Medical and
Clinical Aspects of Aging. H. T. Blumenthal, Ed., Columbia Univ. Press, New York, USA,
1962, 4, p. 272-292.
10. Matei V.Cet al.: The Effects of Gerovital-H3
Treatment on Antigen-Induced Arthritis in Rabbits. Romanian J. Geront. & Geriatrics.
1984, 5, 1, 55-63.
11. Aslan A., David C. et al.: Gerovital-H3 Original
Product. Ed. Ministry of Chemical Industry. Bucharest, 1977.
12. Aslan A.: Theoretical Bases of Procaine Therapy
in the ‘Prophilaxis of Ageing. Romainan J. Geront. Geriatrics. 1980, 1, 1, 5-15.
13. Dumitru M. et al.: Double Blind Study on
Gerovital-H3 Treatment in the Elderly with Arthritis. Romanian J. Geront. Geriatrics.
1985, 6, 4, 257-263.
ALL INFORMATION IS EDUCATIONAL AND SHOULD NOT REPLACE THE ADVICE OF YOUR PHYSICIAN.
The above article is copyrighted and may
not be copied without the written permission of International Antiaging Systems,
Les Autelets Suite A, Sark GY9 0SF, Channel Islands, UK.
HOME
to order
International
Antiaging Systems
Les Autelets Suite A
Sark GY9 0SF
Channel Islands
Great Britain
phone: 44-870-151-4144 (Britain)
contact us
we do not accept telephone orders
we do not ship to the United Kingdom
|
